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Recent advancements in genetic research have uncovered new forms of monogenic osteoporosis, 34 
expanding our understanding of the molecular pathways regulating bone health. Despite active 35 
research, knowledge on the pathomechanisms, disease-specific biomarkers and optimal treatment 36 
in these disorders is still limited. Mutations in WNT1, encoding a WNT/-catenin pathway ligand 37 
WNT1, and PLS3, encoding X chromosomally inherited plastin 3 (PLS3), both result in early-onset 38 
osteoporosis with prevalent fractures and disrupted bone metabolism. However, despite marked 39 
skeletal pathology, conventional bone markers are usually normal in both diseases. Our study aimed 40 
to identify novel bone markers in PLS3 and WNT1 osteoporosis that could offer diagnostic potential 41 
and shed light on the mechanisms behind these skeletal pathologies. We measured several 42 
parameters of bone metabolism, including serum dickkopf-1 (DKK1), sclerostin, and intact and C-43 
terminal fibroblast growth factor 23 (FGF23) concentrations in 17 WNT1 and 14 PLS3 mutation-44 
positive subjects. Findings were compared with 34 healthy mutation-negative subjects from the 45 
same families. Results confirmed normal concentrations of conventional metabolic bone markers in 46 
both groups. DKK1 concentrations were significantly elevated in PLS3 mutation-positive subjects 47 
compared with WNT1 mutation-positive subjects (p<0.001) or the mutation-negative subjects 48 
(p=0.002). Similar differences were not seen in WNT1 subjects. Sclerostin concentrations did not 49 
differ between any groups. Both intact and C-terminal FGF23 were significantly elevated in WNT1 50 
mutation-positive subjects (p=0.039 and 0.027, respectively) and normal in PLS3 subjects. Our 51 
results indicate a link between PLS3 and DKK1 and WNT1 and FGF23 in bone metabolism. The 52 
normal sclerostin and DKK1 levels in patients with impaired WNT signaling suggest another parallel 53 
regulatory mechanism. These findings provide novel information on the molecular networks in 54 
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bone. Extended studies are needed to investigate whether these biomarkers offer diagnostic value 55 
or potential as treatment targets in osteoporosis.  56 
 57 





The discovery of new forms of monogenic osteoporosis has brought an abundance of new 61 
knowledge on the molecular pathways and specific proteins participating in bone health 62 
maintenance. In 2013, we and others showed that WNT1 is a key ligand to the WNT pathway in 63 
bone as monoallelic and biallelic mutations in WNT1 were identified to cause severe and early-onset 64 
autosomal dominant osteoporosis and autosomal recessive osteogenesis imperfecta, 65 
respectively(1). The mutated WNT1 leads to low activation of the WNT pathway, decreased 66 
expression of target genes and consequently low bone turnover, low bone mineral density (BMD) 67 
and prevalent fractures(1). Similarly, in 2013, mutations in Plastin 3–encoding PLS3, were reported 68 
to result in X-linked childhood-onset osteoporosis with frequent peripheral and vertebral 69 
compression fractures and low bone turnover with heterogenous and defective mineralization in 70 
bone biopsies(2–5). Due to its X-chromosomal inheritance pattern, the phenotype is typically more 71 
severe in affected males, while females have normal to increased skeletal fragility(2,3).  72 
 73 
The molecular mechanisms by which WNT1 and PLS3 modulate bone metabolism are very different. 74 
WNT signaling regulates bone cell development and differentiation directly and is a crucial 75 
component of skeletal development and homeostasis from early fetal development all throughout 76 
childhood growth and adulthood maintenance(6). Its aberrant activation has previously been 77 
demonstrated in several monogenic bone diseases with severe skeletal pathology; mutations in the 78 
transmembrane co-receptor low-density lipoprotein receptor-related protein 5 (LRP5) lead to 79 
osteoporosis-pseudoglioma syndrome and high bone mass disorder(7), and mutations in SOST, 80 
encoding WNT-pathway inhibitor sclerostin, result in sclerosing bone diseases sclerosteosis and van 81 
Buchem disease(8,9). Furthermore, genome-wide association studies have highlighted the pathway’s 82 
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role in bone health and the pathway is currently recognized as a preferable target for novel 83 
osteoporosis drugs(10,11). The functions of PLS3 in bone metabolism, on the other hand, are still 84 
largely unidentified. Animal studies indicate a role in regulation of cytoskeletal actin bundling(12) and 85 
their mechanosensory apparatus(2), and studies on patients’ bone biopsies suggest involvement in 86 
osteoclast function as well as bone matrix mineralization(5). However, the exact functions of PLS3 87 
and the pathways which its actions diverge with remain elusive. 88 
 89 
Vertebral fractures are a common feature in both WNT1 and PLS3 osteoporosis while the incidence 90 
of peripheral fractures varies. DXA-derived BMD values range from normal to severely reduced 91 
depending on patient age, gender and type of mutation(1,3–5). Furthermore, despite the distinct 92 
skeletal pathologies, conventional metabolic bone markers have been reported to be normal in 93 
affected WNT1 and PLS3 mutation-positive subjects(1,3,13,14). This great variability in clinical 94 
presentation often complicates and delays diagnosis. Therefore, we set out to evaluate, in addition 95 
to the conventional bone turnover markers, the circulating concentrations of dickkopf-1 (DKK1; 96 
dickkopf WNT signaling pathway inhibitor 1), sclerostin, and fibroblast growth factor 23 (FGF23) in 97 
WNT1 and PLS3 mutation-positive subjects to identify potential biomarkers for these two bone 98 
diseases and to further elucidate the molecular mechanisms behind their disturbed bone 99 
metabolism. All three markers—DKK1, sclerostin and FGF23—are mainly secreted by the 100 
osteocytes. Sclerostin and DKK1 are known inhibitors of WNT signaling in bone and target molecules 101 
for novel osteoporosis drugs, namely anti-sclerostin and anti-DKK1 antibodies(11,15). FGF23 is a 102 
hormone partaking in the regulation of serum phosphate concentration through renal excretion and 103 
intestinal absorption(16) although additional functions have also been suggested in e.g. iron 104 
metabolism, inflammation and erythropoiesis(17,18). Furthermore, we have previously reported 105 
altered osteocyte protein expression in bone biopsies of patients with WNT1 and PLS3 106 
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osteoporosis(19). Here, we report intriguing and counterintuitive findings of significantly elevated 107 
and gender-dependent concentrations of DKK1 in PLS3 mutation-positive subjects and normal 108 
concentrations in WNT1 mutation-positive subjects, and significantly elevated FGF23 109 
concentrations in WNT1 mutation-positive subjects.  110 
 111 
Patients and methods 112 
 113 
Subjects 114 
We recruited WNT1 mutation-positive subjects from two large Finnish families (Family A and B) with 115 
the same heterozygous missense mutation p.C218G in WNT1 as reported elsewhere(1,13,14). For the 116 
present study, we offered participation to all previously identified mutation-positive subjects 117 
(n=25). A control group, with similar genetic background and representing all age groups and both 118 
genders, was formed by offering participation to mutation-negative individuals in these two families 119 
(n=32). Altogether, 17 mutation-positive and 17 mutation-negative individuals consented from 120 
these two families. 121 
 122 
We recruited PLS3 mutation-positive subjects from four previously identified Finnish families with 123 
different PLS3 mutations(3,4,17): Family C = an intronic splice site mutation c.73-24T>A 124 
(p.Asp25Alafs*17)(3), Family D = a 12.5 kb tandem duplication spanning intron 2 to 3 of PLS3(20), 125 
Family E = a nonsense mutation c.766C>T (p.Arg256*)(4), and Family F = a de novo heterozygous 126 
missense mutation c.1424A>G (p.N446S)(4). We offered participation to all mutation-positive 127 
individuals (n=14, n=3, n=2, n=1, respectively) in these four families. Similarly, participation was also 128 
offered to mutation-negative individuals from the same four families. Altogether, 14 mutation-129 




Upon participation, all subjects signed a written informed consent to participation in the study. All 132 
genetic and clinical studies were approved by the Research Ethics Board of Helsinki University 133 
Hospital. 134 
 135 
Genetic evaluations 136 
We have previously, in our prior studies on monogenic forms of osteoporosis, identified the same 137 
WNT1 mutation in two unrelated Finnish families(1,13) and four different PLS3 mutations in four 138 
Finnish families(3,4,20). These were identified using different methods, including targeted Sanger 139 
sequencing, whole-genome sequencing, and custom-made array-comparative genomic 140 
hybridization ((1,3,4,13,20). In the current study, we screened all participating study subjects for the 141 
pertinent gene mutation with conventional Sanger sequencing on DNA extracted from peripheral 142 
blood as previously described(13).  143 
 144 
Clinical assessments 145 
We gathered data on previous fractures and prior or current osteoporosis and other medications 146 
by patient questionnaires and from hospital records. BMD measures were collected from previously 147 
performed dual-energy X-ray absorptiometry–assessments, which were all performed at different 148 
time points and using different machines. Measured BMD values are given as Z-scores, calculated 149 
using equipment-specific normative data; these are used to roughly compare and differentiate 150 
between normal and osteoporotic BMD status.  151 
 152 
Biochemical evaluations 153 
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We collected all blood samples in the morning between 8 and 9 a.m. after an overnight fast. Serum 154 
aliquots were immediately stored at –80°C until analyses. Serum concentrations of ionized calcium, 155 
phosphate and alkaline phosphatase (ALP), and urinary phosphate and creatinine were analyzed by 156 
routine clinical laboratory assays at the HUSLAB Laboratory, Helsinki, Finland. Serum 25-157 
hydroxyvitamin D concentrations were determined with a chemiluminescent immunoassay (CLIA) 158 
on two analyzers: the Architect i2000SR analyzer (Abbott, Deerfield, IL, USA) with an assay 159 
performance of: analytical range 10–300 nmol/L, intra-assay coefficient of variation (CV) of <6%, 160 
and interassay CV <8%; and the Advia Centaur XPT analyzer (Siemens, Raritan, NJ, USA) with an 161 
assay performance of: analytical range 10.5–375 nmol/L, intra-assay CV of <6%, and interassay CV 162 
<9%. Serum 1,25-dihydroxyvitamin D was analyzed by CLIA on a LIAISON XL analyzer (DiaSorin, 163 
Stillwater, MN, USA) with an assay performance of: analytical range 12–480 pmol/L, intra-assay CV 164 
of <4%, and interassay CV <5%. Both parathyroid hormone (PTH) and collagen type 1 cross-linked 165 
C-telopeptide (CTX; a bone resorption marker) were assessed with CLIA assays on the IDS-iSYS fully 166 
automated immunoassay system (Immunodiagnostic Systems, Ltd., Bolton, UK). The PTH assay 167 
performance was as follows: analytical range 5–5000 pg/mL, intra-assay CV of <4%, and interassay 168 
CV <5%. The CTX assay performance was as follows: analytical range 0.033–6.000 ng/mL, intra-assay 169 
CV of <6%, and interassay CV <10%. Serum intact FGF23 was determined by an enzyme-linked 170 
immunosorbent assay (ELISA) (Kainos Laboratories, Inc., Tokyo, Japan) with an assay performance 171 
of: analytical range 8–800 pg/mL, intra-assay CV of <6%, and interassay CV of <10%. Serum C-172 
terminal FGF23 was assessed by ELISA (Biomedica, Vienna, Austria) with an assay performance of: 173 
analytical range 0.1–20.0 pmol/L, intra-assay CV of <12%, and interassay CV <10%. Serum DKK1 was 174 
measured by ELISA (Biomedica) with an assay performance of: analytical range 1.7–160 pmol/L, 175 
intra-assay CV of <3%, and interassay CV <5%. Serum sclerostin was determined by ELISA 176 
(Biomedica) with an assay performance of: analytical range 3.2–240 pmol/L, intra-assay CV of <7%, 177 
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and interassay CV <10%. Serum type I procollagen intact N-terminal propeptide (PINP) was assessed 178 
with the UniQ radioimmunoassay (Orion Diagnostica, Espoo, Finland) with an assay performance of: 179 
analytical range 5–250 µg/L, intra-assay CV of <5%, and interassay CV <6%. All samples were run in 180 
duplicates and in full accordance with the manufacturers’ instructions for all biochemical assays. 181 
 182 
Statistical analyses 183 
Descriptive data are reported as median and range when appropriate. Normality of data was 184 
assessed by the Kolmogorov–Smirnov and Shapiro–Wilk tests, and visually using histograms. 185 
Unpaired two-tailed Student’s t test, Mann–Whitney U test, and Pearson correlation were used as 186 
appropriate (SPSS Statistics 24; IBM Corporation, Armond, NY, USA). p-values <0.05 were 187 





The current study comprised a total of 17 WNT1 mutation-positive subjects (12 females, age range 193 
11–76 years, median 52 years) from two families with a WNT1 missense mutation p.C218G (Families 194 
A and B) and 14 PLS3 mutation-positive subjects (9 females, 8–76 years, median 41 years) from four 195 
families with different PLS3 mutations (Families C–F) (Figure 1, Table 1). The control subjects 196 
consisted of altogether 34 mutation-negative individuals (17 females, 8–77 years, median 36 years) 197 
from these same six families (Figure 1, Supplemental Table 1).  198 
 199 
The mutation-positive subjects had varying histories of previous fractures (range 0 to >10 fractures), 200 
vertebral compression fractures and osteoporosis medications (Figure 1, Table 1). Treatment for 201 
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osteoporosis was ongoing for three subjects at the time of study. Another three subjects received 202 
inhaled glucocorticoid treatment for asthma with low to moderate dosages. The mutation-negative 203 
subjects also had varying histories of previous fractures (range of peripheral fractures 0–9) but none 204 
had ongoing osteoporosis medication at the time of the study (Supplemental Table 1). Six of the 205 
subjects had ongoing glucocorticoid treatment for asthma; all were in low to moderate dosages and 206 
given in inhaled form. 207 
 208 
Biochemical markers of bone and mineral metabolism 209 
Evaluations of serum ionized calcium, phosphate, 1,25-dihydroxy- and 25-hydroxyvitamin D and 210 
PTH, and urinary phosphate concentrations showed mostly normal and only isolated findings of 211 
supra- and subnormal values in both mutation-positive and mutation-negative subjects; no 212 
differences between the groups were noted (Figure 2, Supplemental Table 2). Similarly, no 213 
differences between the groups were observed for the bone turnover markers PINP, ALP and CTX 214 
(Figure 2, Supplemental Table 2).  215 
 216 
DKK1, sclerostin and FGF23 concentrations  217 
We observed no significant differences in serum DKK1 between the WNT1 mutation-positive 218 
(median 27.3 pmol/L; range 13.2–58.9 pmol/L) and the mutation-negative (median 27.9 pmol/L; 219 
4.4–81.8 pmol/L) subjects (p=0.583) (Figure 3, Supplemental Table 2). Correspondingly, the serum 220 
sclerostin concentrations were similar between the WNT1 mutation-positive and the mutation-221 
negative subjects: 19.5 pmol/L (8.9–34.0 pmol/L) and 19.8 pmol/L (4.3–123 pmol/L), respectively 222 




On the contrary, both C-terminal and intact FGF23 concentrations were significantly elevated in the 225 
WNT1 mutation-positive subjects compared with the mutation-negative subjects (medians 1.51 vs 226 
0.96 pmol/L and 54.9 vs 51.4 pg/mL; p=0.027 and p=0.039, respectively) (Figure 4, Supplemental 227 
Table 2). Of note, despite elevated FGF23, serum and urinary phosphate concentrations were similar 228 
between the mutation-positive and negative subjects (Supplemental Table 2). 229 
 230 
We found DKK1 to be significantly elevated in the PLS3 mutation-positive subjects in comparison 231 
with the WNT1 mutation-positive subjects (medians 27.3 pmol/L (13.2–58.9 pmol/L vs 53.3 pmol/L, 232 
p<0.001) and mutation-negative subjects (27.9 pmol/L (4.4–81.8 pmol/L), p=0.002) (Figure 3, 233 
Supplemental Table 2). Post-hoc analysis by gender confirmed that female PLS3 mutation-positive 234 
subjects (n=9) had significantly increased DKK1 concentrations in comparison with female mutation-235 
negative subjects (n=17) (p=0.009) (Figure 3). The difference for PLS3 mutation-positive males (n=5) 236 
vs mutation-negative males (n=17) was less distinct (p=0.100) (Figure 3). The DKK1 concentrations 237 
in the PLS3 mutation-positive subjects did not vary depending on age (r=0.192; p=0.510) nor 238 
depending on past or ongoing osteoporosis medication (Figure 2). Sclerostin concentrations did not 239 
differ between the PLS3 mutation-positive and the mutation-negative subjects: 17.4 pmol/L (5.0–240 
43.0 pmol/L) vs 19.8 pmol/L (4.3–123.0 pmol/L) (p=1.000) (Figure 3). No significant differences were 241 
noted in FGF23 concentrations between the PLS3 mutation-positive and the mutation-negative 242 




This study is the first to systematically assess several conventional and new bone markers, including 247 
DKK1, sclerostin, and intact and C-terminal FGF23, in a large cohort of pediatric and adult subjects 248 
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with WNT1 or PLS3 mutations. Mutations in WNT1 and PLS3 are known to cause severe, early-onset 249 
osteoporosis with frequent fractures, low BMD, and on the tissue level, low bone turnover and 250 
distinct bone pathology(1,3,4,13). While the skeletal consequences of aberrant WNT1 signaling are 251 
quite well understood, the primary pathways and molecular mechanisms by which abnormal PLS3 252 
function results in skeletal disease are still largely unknown. Additionally, recognizing the inaccuracy 253 
of conventional metabolic bone markers in evaluating bone health in osteoporotic patients(21) and 254 
their normality in low-turnover, monogenic and collagen-independent skeletal disorders(1,3,13,14), 255 
evaluating alternate biomarkers offers novel information and potential targets for future diagnostic 256 
and therapeutic means. We report novel findings suggesting a link between PLS3 and DKK1 in bone 257 
metabolism with an increase in serum DKK1. In addition, we report normality of DKK1 and sclerostin 258 
in WNT1-related bone disease, but elevated serum intact and C-terminal FGF23 in WNT1 mutation-259 
positive subjects. These findings shed light on possible pathomechanisms behind these skeletal 260 
disorders and on the key proteins governing bone health. 261 
 262 
WNT pathway is a key regulator of skeletal development from early fetal period to all throughout 263 
childhood, adolescent growth and mature bone homeostasis in adulthood and its aberrant 264 
activation leads to several skeletal disorders of both low and high bone mass(7–9). DKK1, encoded by 265 
DKK1, is an inhibitor of the WNT signaling pathway and thus an important factor maintaining 266 
balanced bone metabolism. Its primary source in bone is presumably osteocytes and the role to 267 
inhibit WNT signaling by binding to the transmembrane dual-receptor complex consisting of LRP5 268 
or LRP6 and seven transmembrane G-protein Frizzled and inactivating this receptor complex(6,22,23). 269 
Sclerostin, encoded by SOST and also secreted by osteocytes, acts in a similar manner by targeting 270 
LRP5/6 and reducing binding of a WNT ligand to the receptor complex(6). WNT signaling is bone 271 
formation–favoring as it promotes first mesenchymal progenitor cell commitment to the 272 
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osteoblastic lineage and then osteoblast differentiation, proliferation and activity. In normal 273 
conditions, WNT signaling and its inhibition by DKK1 and sclerostin are kept at refined balance to 274 
maintain sufficient and to detain excessive bone formation. Serum concentrations of sclerostin are 275 
reported to vary between different age groups and genders and also largely depending on the 276 
method used for analysis(24,25,26,27). For DKK1, on the other hand, information about its association 277 
with age or gender is limited and from the few studies reported, no association was observed.   278 
 279 
The heterozygous WNT1 mutation p.C218G leads to decreased activation of the WNT pathway, low 280 
target gene transcription and consequently low bone formation and turnover(1). DKK1 and sclerostin 281 
function to inhibit WNT signaling and in the presence of decreased WNT pathway activation due to 282 
the mutated WNT1, one would hypothesize that this would lead to decreased concentrations of the 283 
pathway’s inhibitors and that concentrations of DKK1 and sclerostin would be subsequently similarly 284 
decreased. The finding of unaltered circulating DKK1 and sclerostin in WNT1 mutation-positive 285 
subjects is unexpected and suggests that no compensatory feed-back mechanisms exist from the 286 
intracellular WNT/-catenin activity to its negative regulators. This particular WNT1 mutation only 287 
leads to haploinsufficiency and slightly reduced WNT1 signaling which may impact the results(1). 288 
Other plausible explanations could be that the actions by DKK1 and sclerostin are outplayed by other 289 
partaking or compensatory mechanisms, or that the communication between WNT1, sclerostin and 290 
DKK1 is not as exclusive as previously thought(21).  291 
 292 
On the contrary, we observed significantly elevated serum concentrations of FGF23 but normal 293 
phosphate parameters in WNT1 mutation-positive subjects. This is congruent to our previous 294 
findings of high expression of FGF23 in bone biopsies from WNT1 mutation-positive subjects(19). The 295 
FGF23 concentrations did not vary depending on age or gender, as supported by general 296 
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assumptions that serum FGF23 concentrations do not associate with age, gender or puberty(28). 297 
Furthermore, we did not find significant differences in serum phosphate or vitamin D concentrations 298 
between the groups. FGF23 is mainly secreted from osteocytes, regulates primarily systemic 299 
phosphate homeostasis and its malfunction is linked to several inherited syndromes with 300 
hypophosphatemic rickets and tumor-induced osteomalacia(29). However, the impact of FGF23 on 301 
serum phosphate levels in normal physiological and osteoporotic conditions is not well described. 302 
We and others have previously reported that neither intact nor C-terminal FGF23 levels correlate 303 
with serum or urinary phosphate in children, suggesting additional roles for FGF23 in bone 304 
metabolism(30,31). This might be reflected in the WNT1 subjects in our study, where additional 305 
mechanisms are likely to be included. The link between FGF23 and WNT1 in bone is unclear and we 306 
have previously postulated that increased FGF23 in response to low WNT signaling—independent 307 
of changes in PTH—could be mediated by altered nuclear receptor–associated protein 1(24,32). 308 
However, given our previous findings of low bone marrow iron storage(27) and the previously 309 
identified link between iron metabolism and FGF23(33,34), the rise in circulating FGF23 could be in 310 
result of an iron-deficient microenvironment in bone. However, these interactions between 311 
different proteins are likely very complex and demand further functional investigations. 312 
  313 
Although PLS3 has an inevitably important role in bone metabolism, as demonstrated by the skeletal 314 
phenotypes in PLS3 mutation-positive patients, the molecular mechanisms behind the grave 315 
skeletal changes are still largely unknown. PLS3 has been shown to modulate actin bundling and 316 
cytoskeletal remodeling and is thought to enable cell endo- and exocytosis, migration and 317 
adhesion(34,35). In bone specifically, PLS3 was first suggested to be involved in osteocytes’ 318 
mechanosensing abilities(2,12), and, more recently, experimental findings suggest involvement in 319 
osteoclastogenesis and osteoclast function through impaired podosome organization(36,37). 320 
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Evaluations of patients’ bone biopsies collectively insinuate a mineralization defect, which could 321 
stem from a combination of these different mechanisms(5,23,39).  322 
 323 
The finding that mutations in PLS3 somehow relay to altered DKK1 secretion is novel and important. 324 
Our group has previously reported delayed and disturbed bone matrix mineralization in a young 325 
male with a PLS3 deletion(5), but the mechanism behind PLS3’s presumed role in matrix 326 
mineralization has remained elusive. Further, although WNT signaling and one of its antagonists 327 
DKK1, are important for bone metabolism and DKK1 has been shown to inhibit matrix mineralization 328 
in a dose-dependent manner(6,39), the mechanism by which defective PLS3 leads to altered DKK1 329 
concentrations is unclear. One plausible explanation could be that the mutated PLS3 affects 330 
osteocyte function, leading to increased DKK1 production and secretion. Saupe et al. have 331 
previously described that drug-induced disruptions in actin cytoskeleton and focal adhesion 332 
signaling impacted DKK1 mRNA levels in tumor cells(40). The effects of PLS3 mutations on DKK1 333 
production could also be indirect, transmitted through other, yet unidentified proteins. Further, the 334 
reason for low bone turnover in PLS3 osteoporosis could reside in defective WNT signaling, which 335 
might also explain the similarities in phenotype between WNT1 and PLS3 mutation-positive 336 
patients. Our post-hoc analysis by gender confirmed the main finding in female patients. Although 337 
DKK1 was elevated also in PLS3 mutation-positive males compared to healthy subjects the post-hoc 338 
analysis did not reach statistical significance, probably due to lack of statistical power based on the 339 
low number of male patients (n=5). Possible gender differences remain unclear and unanswered by 340 
our study and demand further investigation. Furthermore, if the changes in DKK1 are due to 341 
cytoskeletal changes and osteocyte dysfunction, it remains unclear why sclerostin concentrations 342 
remain unaltered. Lastly, the normality of the osteocyte-derived FGF23 in PLS3 subjects is also an 343 




Both DKK1 and sclerostin are target molecules for novel osteoporosis treatments; anti-DKK1 and 346 
anti-sclerostin antibodies are to counteract these proteins’ inhibitory actions and enhance WNT-347 
driven bone formation(11,15). While promising in postmenopausal osteoporosis treatment(11,15), their 348 
therapeutic efficiency in WNT1- or PLS3-related bone diseases are yet to be verified. For WNT1 349 
osteoporosis, the unexpected normality in sclerostin concentrations could indicate that anti-350 
sclerostin antibody might be a very effective treatment modality for WNT1 mutation-positive 351 
subjects. Since the low WNT signaling in WNT1 mutation-positive subjects is not corrected by 352 
feedback regulation to subsequently reduce the negative effect of DKK1 and sclerostin, it is possible 353 
that their inhibitory effect on the WNT pathway amplifies the effect of absent WNT stimulus on 354 
bone metabolism, further reducing bone formation and contributing to the skeletal phenotype. 355 
Moreover, the relatively high concentrations of DKK1 and sclerostin could partly explain the severe 356 
bone phenotype in heterozygote WNT1 subjects. Correspondingly, the surprising finding of elevated 357 
DKK1 in PLS3 mutation-positive subjects might imply that this could similarly be a suitable route for 358 
effective treatment in PLS3 osteoporosis. Lastly, with novel anti-FGF23 antibodies providing positive 359 
findings in preliminary mouse studies and clinical trials(41), similar approaches could be taken to 360 
evaluate to efficiency of blocking FGF23 signaling to enhance bone quality in WNT1-related bone 361 
disorders.   362 
 363 
While conventional markers of bone turnover are typically informative when monitoring treatment 364 
response, their value in evaluating altered turnover in individual patients is limited, even in high-365 
turnover cases(24). In WNT1 and PLS3 mutation-positive subjects, the conventional metabolic 366 
markers are normal despite clear skeletal phenotypes and increased bone fragility(1,3,14,15). One 367 
reason can be that recommended bone markers for clinical use, i.e. CTX and PINP(24), mainly reflect 368 
19 
 
turnover of collagen type I, while PLS3 and WNT1 osteoporosis are associated with collagen-369 
independent, partly still unidentified biological mechanisms. In addition, both conditions are 370 
identified as low-turnover osteoporosis, whereby the sensitivity of conventional bone markers is an 371 
additional limitation for identifying alterations.  372 
 373 
We acknowledge certain limitations in our study. These primarily concern the small cohort size of 374 
mutation-positive subjects and the lack of longitudinal assessment of how DKK1 and sclerostin 375 
concentrations might respond to disease progression or osteoporosis treatment. For this reason, 376 
we were not able to assess whether these biomarkers could be used as predictive markers of future 377 
fractures, which should be evaluated in future studies. We also were not able to fully evaluate 378 
possible correlation between the biomarker concentrations and BMD. Since the patients originated 379 
from various parts of the country, BMD assessments were performed using different DXA machines 380 
and therefore we were able to only use Z-values from equipment-specific normative data. Some 381 
study participants, among both the mutation-positive and mutation-negative subjects, received 382 
inhaled glucocorticoid treatment at the time of the study. None of these subjects, however, were 383 
treated with high dosages or with oral glucocorticoids. Since the impact of inhaled glucocorticoids 384 
was regarded minimal(42), we did not exclude them from the study. Furthermore, the selection of 385 
the mutation-negative individuals for the control group was based solely on family relations, in 386 
order to have groups with similar overall genetic backgrounds, while disregarding age, gender or 387 
menopausal status as inclusion or exclusion criteria. Lastly, in the premise of this study, we were 388 
not able to further functionally evaluate for example bone tissue expression of DKK1 or sclerostin 389 
or the detailed communications between these proteins. The potential of improving bone health in 390 
these patients by targeting these molecules remains to be elucidated in future studies. Nonetheless, 391 
given the rarity of both WNT1 and PLS3 mutation-positive subjects, a control group of individuals 392 
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from the same families and the novelty of the research topic, we consider our results to be highly 393 
valuable and provide unique and novel information on the molecular mechanisms behind these 394 
monogenic skeletal pathologies. 395 
 396 
In conclusion, our results intriguingly indicate increased DKK1 concentration in PLS3 osteoporosis 397 
and suggest a link between PLS3 and DKK1 in bone metabolism. Sclerostin concentrations are 398 
normal in WNT1 and PLS3 osteoporosis but FGF23 may be impacted by abnormal WNT1 signaling. 399 
These findings provide novel information on the molecular communications in bone and open up 400 
new avenues for focused studies on mechanisms in PLS3- and WNT1-related skeletal disorders. 401 
DKK1 and FGF23 may be clinically useful biomarkers for PLS3 and WNT1 osteoporosis, respectively. 402 
Future studies should investigate the relevance of these findings in larger patient cohorts and in 403 
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Figure 1. Pedigrees of the six included Finnish families with WNT1 and PLS3 mutations. A) and B) 589 
WNT1 missense mutation c.652T>G (p.C218G) C) PLS3 intronic splice site mutation c.73–24T>A 590 
(p.Asp25Alafs*17), D) intragenic tandem duplication within PLS3, E) PLS3 de novo heterozygous 591 
missense mutation c.1424AG> (p.N466S), and F) PLS3 nonsense mutation c.766C>T (p.Arg256*). The 592 
pedigrees have been modified to ensure anonymity. Squares represent males, circles females. 593 
 594 
Figure 2. Scatter plots of bone turnover marker serum concentrations in 17 WNT1 mutation-595 
positive and 14 PLS3 mutation-positive subjects and 34 mutation-negative subjects. A) 596 
Parathyroid hormone (PTH); B) Collagen type 1 cross-linked C-telopeptide (CTX-1); C) Alkaline 597 
phosphatase (ALP); D) Type I procollagen intact N-terminal propeptide (PINP); E) Sclerostin; F) 598 
Dickkoph-1 (DKK1); and fibroblast growth factor 23 (FGF23) in G) intact and H) C-terminal form. Blue 599 
represents WNT1 subjects, red PLS3 subjects, gray circles mutation-negative subjects. The WNT1 600 
mutation-positive subjects harbor a heterozygous WNT1 missense mutation c.652T>G (p.C218G). 601 
The PLS3 mutation-positive subjects harbor different PLS3 mutations: nine with an intronic splice 602 
site mutation c.73–24T>A (p.Asp25Alafs*17), three with a duplication of exon 3, and two with a 603 
nonsense mutation c.766C>T (p.Arg256*). Subjects with ongoing osteoporosis treatment at the 604 
time of the study are indicated by black marker outlines.  605 
 606 
Figure 3. Box plots of serum DKK1 and sclerostin concentrations in 17 WNT1 mutation-positive 607 
subjects (A–B) and 14 PLS3 mutation-positive subjects (C–D) compared with 34 healthy mutation-608 
negative subjects. MP = mutation-positive, MN = mutation-negative, F = female, M = male. The PLS3 609 
mutation-positive subjects harbor different mutations: seven with heterozygous and two with 610 
31 
 
hemizygous deletion c.73–24T>A (p.Asp25Alafs*17); one with heterozygous and two with 611 
hemizygous duplication of exon 3; and one with heterozygous and one with hemizygous nonsense 612 
mutation c.766C>T (p.Arg256*). All WNT1 mutation-positive subjects harbor a heterozygous 613 
missense mutation c.652T>G (p.C218G). For B) and D) the scale has been adjusted for visual clarity, 614 
leaving one outlier (MN-34; 123 pmol/L) outside the graph. p-values derived from Mann–Whitney 615 
U test. 616 
 617 
Figure 4. Box plots of serum intact and C-terminal FGF23 concentrations in 17 WNT1 mutation-618 
positive subjects (A–B) and 14 PLS3 mutation-positive subjects (C–D) compared with 34 healthy 619 
mutation-negative subjects. MP = mutation-positive, MN = mutation-negative, F = female, M = 620 
male, I = intact, C = C-terminal. The PLS3 mutation-positive subjects harbor different mutations: 621 
seven with heterozygous and two with hemizygous deletion c.73–24T>A (p.Asp25Alafs*17); one 622 
with heterozygous and two with hemizygous duplication of exon 3; and one with heterozygous and 623 
one with hemizygous nonsense mutation c.766C>T (p.Arg256*). All WNT1 mutation-positive 624 
subjects harbor a heterozygous missense mutation c.652T>G (p.C218G). For B) the scale has been 625 
adjusted for visual clarity, leaving one outlier (WNT1-2; 11.02 pmol/L) outside the graph. p-values 626 




























LS Fem WB 
WNT1 mutation-positive subjects 
WNT1 mutation-positive subjects n=17; median age 52 years; 12 females/5 males; % of postmenopausal females (of all, of females) 35%, 75% 
WNT1 mutation-negative subjects n=17; median age 31 years; 8 females/9 males; % of postmenopausal females (of all, of females) 6%, 11% 
WNT1-1, A F 11 1 No No None No No -0.5 0.0 -0.5 
WNT1-2, A F 13 1 No No None No No -2.1 -1.3 N/A 
WNT1-4, A F 17 9 No Yes* PAM No No -2.5 -0.5 -1.0 
WNT1-6, A F 34 2 No No None No No -1.5 -2.2 -2.2 
WNT1-7, A F 44 0 No No None No No -1.4 -0.9 N/A 
WNT1-8, A F 48 >5 Yes Yes, 3 ZOL No No -1.2 -2.4 -2.0 
WNT1-9, A F 52 0 No No None No Yes N/A N/A N/A 
WNT1-11, A F 53 5 Yes Yes, 2 DMAB No Yes -2.0 -1.0 -1.1 
WNT1-12, A F 54 0 No No None No Yes -3.3 -1.1 -1.5 
WNT1-14, B F 68 1 Yes No None No Yes 0.2 -1.0 -1.5 
WNT1-15, A F 71 9 Yes Yes, 12 EST, RIS Yes Yes -1.5 -1.6 N/A 
WNT1-16, A F 74 6 Yes Yes* 
ALN, PTH, ZOL, 
DMAB 
No Yes -0.8 -1.9 N/A 
WNT1-3, A M 13 4 No No None No N/A -1.1 -0.5 -0.7 
WNT1-5, A M 19 2 No No None No N/A -2.2 -0.1 N/A 
WNT1-10, A M 52 2 Yes No None No N/A -2.8 -1.3 -2.3 
WNT1-13, A M 63 3 Yes Yes, 5 ZOL, PTH No N/A -2.2 -1.3 -3.5 
WNT1-17, A M 76 1 Yes Yes, 6 ZOL, PTH No N/A 0.1 0.0 N/A 
PLS3 mutation-positive subjects 
33 
 
PLS3 mutation-positive subjects n=14; median age 41 years; 9 females/5 males; % of postmenopausal females (of all, of females) 21%, 33% 
PLS3 mutation-negative subjects n=17; median age 39 years; 9 females/8 males; % of postmenopausal females (of all, of females) 18%, 25% 
PLS3-2, C F 11 0 No No None No No N/A N/A N/A 
PLS3-3, C F 14 0 No No None No No N/A N/A N/A 
PLS3-4, C F 15 0 No No None Yes No -2.2 -1.2 -1.1 
PLS3-7, D F 41 0 Yes No None Yes No N/A N/A N/A 
PLS3-8, C F 41 0 Yes Yes* ZOL No No -2.2 -1.5 -2.0 
PLS3-10, C F 48 0 No No None No No -0.6 0.5 -0.6 
PLS3-11, C F 51 0 Yes Yes, 5 PTH No Yes -1.3 N/A -0.7 
PLS3-12, E F 57 1 No No None No Yes 1.2 1.1 -0.7 
PLS3-13, C F 69 >10 Yes Yes, 4 PTH, ZOL No Yes -2.3 -0.6 -1.9 
PLS3-1, D M 8 2• Yes No None No N/A N/A N/A N/A 
PLS3-5, D M 21 1 Yes Yes, 9 ZOL No N/A -0.3 -1.4 -0.2 
PLS3-6, E M 32 4 Yes None None No N/A -4.1 -3.3 -4.5 
PLS3-9, C M 45 10• Yes Yes, 7 ZOL No N/A -1.9 -1.8 -2.5 
PLS3-14, C M 76 4 Yes Yes, 4 ZOL No N/A -2.2 N/A -2.3 
 
Mutation-positive subjects from families A and B harbor a heterozygous WNT1 missense mutation c.652T>G (p.C218G). Mutation-positive subjects from 
families C to F harbor different PLS3 mutations: Family C = intronic splice site mutation c.73–24T>A (p.Asp25Alafs*17), Family D = duplication of exon 3, Family 
E = nonsense mutation c.766C>T (p.Arg256*). F = female, M = male, LS = lumbar spine, Fem = femoral neck, WB = whole body, ALN = alendronate, ZOL = 
zoledronic acid, PTH = teriparatide, DMAB = denosumab, EST = estrogen, RIS= risedronate, PAM = pamidronate. 
• Last fracture within 12 months prior to the study 
* Ongoing osteoporosis medication at the time of study 
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Figure 3. Box plots of serum DKK1 and sclerostin concentrations in 17 WNT1 mutation-positive subjects (A–B) and 14
PLS3 mutation-positive subjects (C–F) compared with 34 age- and gender-matched mutation-negative subjects. MP =
mutation-positive, MN = mutation-negative, F = female, M = male. The PLS3 mutation-positive subjects harbor different
mutations: seven with heterozygous and two with hemizygous deletion c.73-24T>A (p.Asp25Alafs*17); one with
heterozygous and two with hemizygous duplication of exon 3; and one with heterozygous and one with hemizygous
nonsense mutation c.766C>T (p.Arg256*). All WNT1 mutation-positive subjects harbor a heterozygous missense
mutation c.652T>G (p.C218G). For figures B) and D) the scale has been adjusted for visual clarity, leaving one outlier
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Supplemental data  
 
Supplemental Table 1. Clinical data for the 34 mutation-negative subjects. 
 










since last dose 
Inhaled 
glucocorticoids* Postmenopausal 
MN-2, A F 9 1 NA No No No 
MN-6, F F 16 1 NA No No No 
MN-8, A F 19 5 NA No Yes No 
MN-9, D F 19 1 NA No Yes No 
MN-10, C F 22 2 NA No No No 
MN-12, A F 25 6 NA No No No 
MN-14, A F 31 2 NA No Yes No 
MN-15, A F 31 2 NA No Yes No 
MN-17, D F 34 0 NA No No No 
MN-18, A F 37 0 NA No No No 
MN-20, F F 39 8 NA No No No 
MN-24, C F 44 0 NA No Yes No 
MN-25, A F 49 0 NA No No No 
MN-26, D F 51 1 NA No No Yes 
MN-28, A F 57 0 NA No No Yes 
MN-30, D F 64 2 NA No No Yes 
MN-31, E F 64 0 NA No No Yes 
MN-1, C M 8 1 NA No No NA 
MN-3, C M 10 0 NA No No NA 
MN-4, A M 10 2 NA No No NA 
MN-5, A M 16 0 NA No No NA 
MN-7, D M 17 0 NA No No NA 
MN-11, A M 24 9 NA No No NA 
MN-13, A M 30 4 NA No No NA 
MN-16, A M 32 3 NA No No NA 
MN-19, D M 38 0 NA No Yes NA 
MN-21, D M 41 3 Yes Yes, 5 No NA 
MN-22, D M 41 1 NA No No NA 
39 
 
MN-23, B M 43 0 NA No No NA 
MN-27, A M 53 0 Yes No No NA 
MN-29, A M 59 1 NA No No NA 
MN-32, D M 68 0 NA No No NA 
MN-33, E M 69 0 Yes Yes, 11 No NA 
MN-34, B M 77 0 NA No No NA 
 




































WNT1 mutation-positive subjects 
WNT1-1, A F, 11 1.26 1.26 90 173 22 258 1.79 820.00 42.0 2.36 37.4 8.9 1.82 
WNT1-2, A F, 13 1.32 1.32 75 140 24 122 1.35 N/A 66.4 11.02 13.2 20.2 0.99 
WNT1-3, A M, 13 1.25 1.25 112 94 8 247 2.95 852.00 77.3 2.01 30.9 15.3 1.90 
WNT1-4, A F, 17 1.25 1.25 116 96 31 77 0.56 43.40 75.5 1.42 27.3 19.5 2.51 
WNT1-5, A M, 19 1.27 1.27 31 168 22 83 0.45 76.10 32.9 6.17 17.2 20.6 2.33 
WNT1-6, A F, 34 1.24 1.24 105 45 40 84 0.15 38.21 63.8 1.51 34.8 14.0 15.09 
WNT1-7, A F, 44 1.32 1.32 82 67 25 51 0.10 39.79 51.0 5.71 27.2 33.9 1.30 
WNT1-8, A F, 48 1.22 1.22 125 98 28 51 0.20 34.59 81.2 2.33 32.7 22.8 1.10 
WNT1-9, A F, 52 1.44 1.44 64 127 82 86 0.84 85.26 52.3 1.04 22.9 16.0 2.41 
WNT1-10, A M, 52 1.24 1.24 74 172 24 50 0.20 25.01 54.7 1.31 27.7 16.9 1.60 
WNT1-11, A F, 53 1.21 1.21 102 103 36 47 0.11 14.69 68.7 1.85 23.5 16.4 1.10 
WNT1-12, A F, 54 1.22 1.22 136 123 31 74 0.71 68.92 46.1 0.71 35.8 19.9 2.25 
WNT1-13, A M, 63 1.24 1.24 146 114 29 52 0.11 30.74 66.1 1.18 19.7 24.6 1.17 
WNT1-14, B F, 68 1.20 1.20 80 119 44 52 0.12 36.47 49.5 0.29 58.9 19.2 1.30 
WNT1-15, A F, 71 1.24 1.24 88 124 18 72 0.20 37.79 41.2 0.81 26.8 15.8 2.05 
WNT1-16, A F, 74 1.25 1.25 97 72 22 48 0.15 22.16 73.4 0.78 33.5 20.1 1.15 
WNT1-17, A M, 76 1.28 1.28 89 88 48 84 0.16 28.30 54.9 1.52 13.3 34.0 0.96 
PLS3 mutation-positive subjects 
PLS3-1, D M, 8 1.34 1.43 77 162 18 262 1.21 332.00 34.6 0.79 31.3 7.7 1.18 
PLS3-2, C F, 11 1.24 1.13 61 189 19 146 2.20 796.00 51.8 0.73 64.0 21.4 1.62 
PLS3-3, C F, 14 1.26 1.45 61 115 34 307 0.69 206.80 47.2 0.75 35.2 16.3 0.84 
PLS3-4, C F, 15 1.26 1.31 34 186 31 100 0.69 75.82 56.8 1.68 60.1 17.5 N/A 
PLS3-5, D M, 21 1.27 1.39 55 185 41 103 0.73 76.71 37.3 1.04 28.2 27.9 2.20 
PLS3-6, E M, 32 1.25 1.03 69 138 31 73 0.29 30.20 65.6 1.79 53.0 25.7 1.73 
PLS3-7, D F, 41 1.27 0.89 46 91 36 89 0.06 23.22 48.6 1.51 28.0 5.0 1.70 
41 
 
PLS3-8, C F, 41 1.22 0.84 43 185 47 43 0.05 14.20 38.7 2.61 68.4 15.4 0.72 
PLS3-9, C M, 45 1.21 1.02 90 156 39 37 0.07 17.12 25.2 0.00 53.6 17.2 2.01 
PLS3-10, C F, 48 1.16 0.85 61 206 78 94 0.14 35.02 39.0 0.79 60.1 14.1 1.81 
PLS3-11, C F, 51 1.19 0.80 85 158 54 64 0.19 34.53 82.2 0.31 54.0 43.0 1.50 
PLS3-12, E F, 57 1.21 1.09 95 109 52 87 0.19 51.82 90.3 1.90 35.7 38.6 0.99 
PLS3-13, C F, 69 1.23 1.05 131 114 28 58 0.16 30.12 71.6 1.13 77.6 41.3 1.66 
PLS3-14, C M, 76 1.21 0.84 69 108 57 49 0.05 17.00 67.4 1.68 36.3 11.7 1.69 
Mutation-negative subjects 
MN-1, C M, 8 1.24 1.42 74 110 27 139 1.46 360.00 14.4 0.90 28.9 19.6 4.25 
MN-2, A F, 9 1.24 1.59 68 165 33 214 1.69 660.00 49.5 0.93 34.1 27.9 N/A 
MN-3, C M, 10 1.25 1.42 59 154 23 179 1.91 490.00 25.5 0.36 36.0 16.4 4.31 
MN-4, A M, 10 1.28 1.55 70 192 13 257 1.64 312.00 37.0 0.39 42.5 21.3 1.15 
MN-5, A M, 16 1.32 1.42 43 157 16 313 1.22 171.00 47.0 0.68 24.6 14.2 1.59 
MN-6, F F, 16 1.20 1.41 69 93 53 93 0.96 130.33 53.6 1.68 16.0 22.1 1.25 
MN-7, D M, 17 1.26 1.22 73 118 35 89 1.21 157.83 51.3 0.78 20.2 4.3 3.16 
MN-8, A F, 19 1.27 1.56 69 100 16 108 0.27 41.67 39.8 1.19 37.4 12.7 1.83 
MN-9, D F, 19 1.29 0.91 60 135 22 63 0.59 79.12 33.7 0.53 54.2 19.9 2.14 
MN-10, C F, 22 1.19 0.99 49 235 39 61 0.53 34.02 22.4 0.12 32.7 12.5 1.95 
MN-11, A M, 24 1.30 1.19 39 144 26 44 0.86 48.07 43.9 1.36 25.4 10.2 3.19 
MN-12, A F, 25 1.24 1.53 70 127 37 67 0.73 50.34 51.6 1.12 23.0 15.3 2.40 
MN-13, A M, 30 1.27 1.38 54 117 39 60 0.38 59.37 56.5 1.07 22.9 26.5 1.01 
MN-14, A F, 31 1.24 0.88 36 68 29 104 0.13 49.08 55.7 2.14 24.2 22.9 2.36 
MN-15, A F, 31 1.30 1.34 26 133 41 66 0.09 53.13 53.1 2.39 26.5 12.0 2.20 
MN-16, A M, 32 1.25 0.91 41 93 30 74 0.33 43.10 65.8 1.15 28.2 14.6 1.15 
MN-17, D F, 34 1.30 0.87 63 269 11 5 0.06 20.55 27.7 2.55 7.8 6.4 0.97 
MN-18, A F, 37 1.27 0.51 60 134 33 67 0.21 34.17 39.5 1.06 18.5 11.3 1.46 
MN-19, D M, 38 1.29 0.83 78 98 27 8 0.27 39.31 52.8 0.9 27.6 9.5 1.41 
MN-20, F F, 39 1.20 0.84 103 103 40 65 0.27 48.89 54.4 0.77 15.4 18.0 1.10 
MN-21, D M, 41 1.23 0.98 84 87 27 46 0.41 58.46 47.0 1.09 69.5 23.6 1.73 
MN-22, D M, 41 1.23 1.05 144 144 57 102 0.71 51.22 60.4 0.66 20.1 22.9 1.51 
MN-23, B M, 43 1.27 1.13 80 74 36 52 0.28 52.74 74.2 0.72 50.5 38.7 1.54 
MN-24, C F, 44 1.18 0.87 77 89 35 49 0.20 38.72 74.2 2.19 81.8 26.1 2.48 
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MN-25, A F, 49 1.22 0.84 90 83 46 61 0.15 31.21 43.7 2.46 35.7 26.9 1.24 
MN-26, D F, 51 1.16 1.27 65 93 56 48 0.27 47.99 32.3 0.53 4.4 29.5 2.75 
MN-27, A M, 53 1.22 1.05 73 57 56 63 0.27 38.77 61.2 1.57 16.6 24.6 2.32 
MN-28, A F, 57 1.28 1.09 39 109 50 50 0.62 70.13 41.2 0.69 44.6 14.5 2.67 
MN-29, A M, 59 1.26 1.08 21 71 31 83 0.22 47.42 77.8 2.61 39.6 26.2 2.18 
MN-30, D F, 64 1.28 1.25 73 143 21 75 0.27 35.59 60.1 0.82 27.1 16.8 2.86 
MN-31, E F, 64 1.18 0.85 112 112 49 73 0.17 27.01 74.4 1.21 58.1 39.0 1.76 
MN-32, D M, 68 1.30 0.79 74 122 35 59 0.28 38.74 42.3 0.98 24.7 16.5 N/A 
MN-33, E M, 69 1.16 0.84 89 119 29 64 0.12 31.49 53.4 0.36 28.8 24.2 1.80 
MN-34, B M, 77 1.28 1.02 87 64 36 94 0.29 23.01 60.9 0.08 37.3 123.0 0.87 
 
F = female, M = male, N/A = not available. Supranormal values are underlined and subnormal values are in bold. Normal ranges according to 
HUSLAB Laboratory (females/males): S-Ca-ion (serum ionized calcium) 1.16-1.3; P-Pi (phosphate) 2–12 years 1.2–1.8, 13–16 years 1.1–1.8, 17 
years 0.8–1.4, females >18 years 0.76–1.41, males 18–49 years 0.71–1.53, males >50 years 0.71–1.23; S-25OHD (vitamin D, nmol/L) >50; normal 
ranges for D-1,25 according to United Medix Laboratories Ltd (1.25-dihydroxyvitamin D) 48–190; ALP (alkaline phosphatase) 8–9 years 115–345, 
10–11 years 115–435/115–335, 12–13 years 90–335/125–405, 14–15 years 80–210/80–445, 16–18 years 35–125/55–330, >18 years 35–105. 
Normal ranges for PTH and CTX using the IDS-iSYS assay (Immunodiagnostic Systems, Ltd., Bolton, UK): PTH adults 11.5–78.4; CTX (collagen type 
1 cross-linked C-telopeptide) pre-menopausal females 0.034–0.635, post-menopausal females 0.034–1.037, males 0.038–0.724. Normal ranges 
for PINP (type I procollagen intact N-terminal propeptide) according to Morovat et al., 2013(42) (females/males): 5–8 years 307–985/200–900, 9–
12 years 386–1070/323–1242, 13–16 years 59.3–672/142–6929, 17–20 years 25.2–160/28.1–369, pre-menopausal women 13.7–71.1, post-
menopausal women 8.2–82.6, men 18–45 years 19.4–95.4, men >45 years 12.8–71.9.  
 
 
